Urelumab, CAS 934823-49-1

Product Description: Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity, and may enhance cytotoxic activity of Rituximab (HY-P9913). Urelumab can be used for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other types of non-Hodgkin lymphoma (NHL)[1].

Applications: COVID-19-immunoregulation

Formula: N/A

References: [1]John Timmerman, et al. Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma. Am J Hematol. 2020 May;95(5):510-520./[2]Cheng LS, et al. A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicity. J Transl Med. 2022 Sep 8;20(1):415.

CAS Number: 934823-49-1

Molecular Weight: N/A

Compound Purity: 97.30

Research Area: Cancer; Inflammation/Immunology

Solubility: H2O

Target: Others

• Artikelnummer: MEXHY-P99055-5
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99055-5
• Green Labware: Nein
• Verpackungseinheit: 5 mg
• Mengeneinheit: STK